APO-BIMATOPROST RC DIN 02403013
Health Canada record
| Active ingredient(s) | BIMATOPROST 0.01 % |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01EE03 BIMATOPROST |
| Original market date | |
| Current status date | 16-Mar-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BIMATOPROST
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02570068 | AG-BIMATOPROST RC | ANGITA PHARMA INC. | Solution | BIMATOPROST 0.01 % | Approved |
| 02356279 | APO-BIMATOPROST | APOTEX INC | Solution | BIMATOPROST 0.03 % | Approved |
| 02402505 | APO-BIMATOPROST | APOTEX INC | Solution | BIMATOPROST 0.03 % | Approved |
| 02529580 | BIMATOPROST RC | JUNO PHARMA CANADA INC. | Solution | BIMATOPROST 0.01 % | Marketed |
| 02570904 | BIMATOPROST RC | SANIS HEALTH INC | Solution | BIMATOPROST 0.01 % | Approved |
| 02567385 | JAMP BIMATOPROST | JAMP PHARMA CORPORATION | Solution | BIMATOPROST 0.03 % | Approved |
| 02565773 | JAMP BIMATOPROST SOLUTION RC | JAMP PHARMA CORPORATION | Solution | BIMATOPROST 0.01 % | Marketed |
| 02350939 | LATISSE | ABBVIE CORPORATION | Solution | BIMATOPROST 0.03 % | Marketed |
| 02324997 | LUMIGAN RC | ABBVIE CORPORATION | Solution | BIMATOPROST 0.01 % | Marketed |
| 02563428 | PRO-BIMATOPROST RC | PRO DOC LIMITEE | Solution | BIMATOPROST 0.01 % | Approved |
| 02429063 | VISTITAN | SANDOZ CANADA INCORPORATED | Solution | BIMATOPROST 0.03 % | Marketed |
| 02533464 | ZIMED PF | LUVO MEDICAL TECHNOLOGIES INC | Solution | BIMATOPROST 0.03 % | Marketed |
| 02245860 | LUMIGAN | ALLERGAN INC | Solution | BIMATOPROST 0.03 % | Cancelled Post Market |
| 02400162 | LUMIGAN PF | ALLERGAN INC | Solution | BIMATOPROST 0.03 % | Cancelled Pre Market |
| 02425521 | SANDOZ BIMATOPROST RC | SANDOZ CANADA INCORPORATED | Solution | BIMATOPROST 0.01 % | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37111 | 2026-03-16 | Abbreviated New Drug Submission (ANDS) | |
| 37107 | 2026-03-16 | Supplement to an Abbreviated New Drug Submission (SANDS) | Update to Product Monograph (to align with CRP approved PM). Product Monograph reformatted to the Master Template. Update to package labels. Change in product name |
International API supply for BIMATOPROST
15 active FDA Drug Master Files.
Request a quote for APO-BIMATOPROST RC